NRIX
Nurix Therapeutics, Inc.$25.66-1.14 (-4.25%)Prev Close$26.80·MCap$2.77B·P/E—·Vol933.1K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
30
$5.49M
◆
Net Activity
Net Seller
$5.49M
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Nurix Therapeutics, Inc. (NRIX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 30 insider sales totaling $5.49M. The most recent insider transaction was by Hansen Gwenn (officer: Chief Scientific Officer), who sold $36.3K worth of shares on Oct 15, 2026. Nurix Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.77B.
NRIX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 1,452 | $25.00 | $36.3K | 117,227 |
| Oct 14, 2026 | GREGORY JULIA P | director | Sell | 22,583 | $23.40 | $528.5K | 10,750-68% |
| Oct 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 5,786 | $23.19 | $134.1K | 9,110-39% |
| Sep 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 5,787 | $25.76 | $149.1K | 9,510-38% |
| Sep 1, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 1,452 | $25.47 | $37.0K | 117,227 |
| Aug 5, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 8,467 | $24.69 | $209.0K | 119,838 |
| Aug 4, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 4,761 | $24.36 | $116.0K | 43,133 |
| Aug 3, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 16,589 | $23.05 | $382.4K | 9,110-65% |
| Jul 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 3,847 | $23.38 | $90.0K | 19,912 |
| Jul 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 3,847 | $23.38 | $90.0K | 121,338 |
| Jul 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 2,845 | $23.38 | $66.5K | 44,927 |
| Jul 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 11,008 | $23.56 | $259.4K | 13,579-45% |
| Jun 25, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 28,935 | $20.06 | $580.5K | 13,579-68% |
| Jun 25, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 5,394 | $20.00 | $107.9K | 115,005 |
| Jun 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $16.60 | $135.3K | 13,579-38% |
| May 5, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 14,055 | $16.60 | $233.3K | 38,174-27% |
| May 4, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $16.96 | $138.2K | 18,305-31% |
| May 1, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 5,394 | $16.76 | $90.4K | 26,453 |
| Apr 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 3,214 | $16.65 | $53.5K | 120,399 |
| Apr 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 2,388 | $16.65 | $39.7K | 51,647 |
| Apr 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 3,214 | $16.65 | $53.5K | 31,847 |
| Mar 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $15.44 | $125.8K | 34,601 |
| Feb 9, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 28,522 | $16.66 | $475.2K | 42,749-40% |
| Jan 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 9,790 | $16.60 | $162.5K | 83,770 |
| Jan 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,842 | $16.60 | $146.8K | 57,098 |
| Jan 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 7,322 | $16.60 | $121.5K | 45,500 |
| Jan 20, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 7,520 | $18.42 | $138.5K | 50,897 |
| Dec 18, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,760 | $17.90 | $67.3K | 0 |
| Nov 24, 2025 | Ring Christine | Chief Legal Officer | Sell | 37,600 | $17.07 | $641.7K | 0 |
| Nov 3, 2025 | van Houte Hans | Chief Financial Officer | Sell | 6,284 | $12.56 | $78.9K | 0 |
| Oct 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 4,087 | $12.80 | $52.3K | 0 |
| Oct 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,644 | $12.80 | $46.6K | 0 |
| Oct 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 3,130 | $12.80 | $40.1K | 0 |
| Aug 1, 2025 | van Houte Hans | Chief Financial Officer | Sell | 5,402 | $11.03 | $59.6K | 0 |
| Jul 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 4,308 | $12.01 | $51.7K | 0 |
| Jul 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,841 | $12.01 | $46.1K | 0 |
| Jul 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 4,304 | $12.01 | $51.7K | 0 |
| May 2, 2025 | van Houte Hans | Chief Financial Officer | Sell | 6,198 | $11.33 | $70.2K | 0 |
| Apr 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,377 | $11.50 | $38.8K | 0 |
| Apr 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 2,894 | $11.50 | $33.3K | 0 |
| Apr 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 2,438 | $11.50 | $28.0K | 0 |
| Mar 3, 2025 | van Houte Hans | Chief Financial Officer | Sell | 5,825 | $14.49 | $84.4K | 0 |
| Feb 3, 2025 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $19.95 | $114.9K | 32,638 |
| Jan 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,690 | $19.85 | $73.3K | 56,270 |
| Jan 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,220 | $19.85 | $63.9K | 32,829 |
| Jan 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 2,811 | $19.85 | $55.8K | 39,803 |
| Jan 2, 2025 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $19.50 | $112.3K | 28,084 |
| Dec 2, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $21.73 | $125.2K | 28,084 |
| Nov 4, 2024 | Ring Christine | Chief Legal Officer | Sell | 3,290 | $25.00 | $82.3K | 28,084 |
| Nov 1, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $24.28 | $139.9K | 28,084 |
Showing 1–50 of 141
1 / 3
NRIX Insider Buying Activity
The following table shows recent insider purchases of Nurix Therapeutics, Inc. (NRIX) stock reported via SEC Form 4 filings.
No insider buying activity found for NRIX in the last 12 months.
NRIX Insider Selling Activity
The following table shows recent insider sales of Nurix Therapeutics, Inc. (NRIX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 1,452 | $25.00 | $36.3K | 117,227 |
| Oct 14, 2026 | GREGORY JULIA P | director | Sell | 22,583 | $23.40 | $528.5K | 10,750-68% |
| Oct 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 5,786 | $23.19 | $134.1K | 9,110-39% |
| Sep 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 5,787 | $25.76 | $149.1K | 9,510-38% |
| Sep 1, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 1,452 | $25.47 | $37.0K | 117,227 |
| Aug 5, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 8,467 | $24.69 | $209.0K | 119,838 |
| Aug 4, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 4,761 | $24.36 | $116.0K | 43,133 |
| Aug 3, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 16,589 | $23.05 | $382.4K | 9,110-65% |
| Jul 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 3,847 | $23.38 | $90.0K | 19,912 |
| Jul 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 3,847 | $23.38 | $90.0K | 121,338 |
| Jul 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 2,845 | $23.38 | $66.5K | 44,927 |
| Jul 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 11,008 | $23.56 | $259.4K | 13,579-45% |
| Jun 25, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 28,935 | $20.06 | $580.5K | 13,579-68% |
| Jun 25, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 5,394 | $20.00 | $107.9K | 115,005 |
| Jun 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $16.60 | $135.3K | 13,579-38% |
| May 5, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 14,055 | $16.60 | $233.3K | 38,174-27% |
| May 4, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $16.96 | $138.2K | 18,305-31% |
| May 1, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 5,394 | $16.76 | $90.4K | 26,453 |
| Apr 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 3,214 | $16.65 | $53.5K | 120,399 |
| Apr 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 2,388 | $16.65 | $39.7K | 51,647 |
| Apr 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 3,214 | $16.65 | $53.5K | 31,847 |
| Mar 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $15.44 | $125.8K | 34,601 |
| Feb 9, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 28,522 | $16.66 | $475.2K | 42,749-40% |
| Jan 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 9,790 | $16.60 | $162.5K | 83,770 |
| Jan 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,842 | $16.60 | $146.8K | 57,098 |
| Jan 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 7,322 | $16.60 | $121.5K | 45,500 |
| Jan 20, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 7,520 | $18.42 | $138.5K | 50,897 |
| Dec 18, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,760 | $17.90 | $67.3K | 0 |
| Nov 24, 2025 | Ring Christine | Chief Legal Officer | Sell | 37,600 | $17.07 | $641.7K | 0 |
| Nov 3, 2025 | van Houte Hans | Chief Financial Officer | Sell | 6,284 | $12.56 | $78.9K | 0 |
| Oct 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 4,087 | $12.80 | $52.3K | 0 |
| Oct 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,644 | $12.80 | $46.6K | 0 |
| Oct 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 3,130 | $12.80 | $40.1K | 0 |
| Aug 1, 2025 | van Houte Hans | Chief Financial Officer | Sell | 5,402 | $11.03 | $59.6K | 0 |
| Jul 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 4,308 | $12.01 | $51.7K | 0 |
| Jul 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,841 | $12.01 | $46.1K | 0 |
| Jul 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 4,304 | $12.01 | $51.7K | 0 |
| May 2, 2025 | van Houte Hans | Chief Financial Officer | Sell | 6,198 | $11.33 | $70.2K | 0 |
| Apr 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,377 | $11.50 | $38.8K | 0 |
| Apr 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 2,894 | $11.50 | $33.3K | 0 |
| Apr 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 2,438 | $11.50 | $28.0K | 0 |
| Mar 3, 2025 | van Houte Hans | Chief Financial Officer | Sell | 5,825 | $14.49 | $84.4K | 0 |
| Feb 3, 2025 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $19.95 | $114.9K | 32,638 |
| Jan 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,690 | $19.85 | $73.3K | 56,270 |
| Jan 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,220 | $19.85 | $63.9K | 32,829 |
| Jan 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 2,811 | $19.85 | $55.8K | 39,803 |
| Jan 2, 2025 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $19.50 | $112.3K | 28,084 |
| Dec 2, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $21.73 | $125.2K | 28,084 |
| Nov 4, 2024 | Ring Christine | Chief Legal Officer | Sell | 3,290 | $25.00 | $82.3K | 28,084 |
| Nov 1, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $24.28 | $139.9K | 28,084 |
NRIX Insiders
Similar Stocks to NRIX
MRNA
Moderna, Inc.
$227.10+2.43%
$85.50B
REGN
Regeneron Pharmaceuticals, Inc.
$963.34+3.82%
$83.15B
RVMD
Revolution Medicines, Inc.
$189.18-1.12%
$39.42B
ALNY
Alnylam Pharmaceuticals, Inc.
$160.28-2.86%
$30.46B
UTHR
United Therapeutics Corporation
$596.63-0.35%
$25.15B
INCY
Incyte Corporation
$119.33-0.88%
$23.69B
INSM
Insmed Incorporated
$110.27-2.06%
$21.18B
EXEL
Exelixis, Inc.
$71.30+2.67%
$16.64B